Paper37101261
Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.
Liu H and 5 others. J Biomed Sci, 2023. Cited by 93 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria. Papers, record 37101261. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37101261
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacteriophages | Major topic |
| Methicillin-Resistant Staphylococcus aureus | Major topic |
| Bacterial Infections | Major topic |
| Humans | |
| Bacteria | |
| Gram-Positive Bacteria | |
| Anti-Bacterial Agents | |
| Endopeptidases |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 31871251 | National Natural Science Foundation of China | PubMed |
Source PubMed
References168
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21048011 | LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. | J Clin Microbiol | 2011 | https://conductscience.org/library/papers/21048011 | PubMed |
| 2 | 12657053 | Functional regulation of the Listeria monocytogenes bacteriophage A118 holin by an intragenic inhibitor lacking the first transmembrane domain. | Mol Microbiol | 2003 | https://conductscience.org/library/papers/12657053 | PubMed |
| 3 | 12499217 | Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. | Antimicrob Agents Chemother | 2003 | https://conductscience.org/library/papers/12499217 | PubMed |
| 4 | 22439788 | Antistaphylococcal activity of bacteriophage derived chimeric protein P128. | BMC Microbiol | 2012 | https://conductscience.org/library/papers/22439788 | PubMed |
| 5 | 25733585 | A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. | J Antimicrob Chemother | 2015 | https://conductscience.org/library/papers/25733585 | PubMed |
| 6 | 18471063 | Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. | J Infect Dis | 2008 | https://conductscience.org/library/papers/18471063 | PubMed |
| 7 | 21535426 | Domain shuffling and module engineering of Listeria phage endolysins for enhanced lytic activity and binding affinity. | Microb Biotechnol | 2011 | https://conductscience.org/library/papers/21535426 | PubMed |
| 8 | 16565432 | Bacteriophage endolysins as a novel class of antibacterial agents. | Exp Biol Med (Maywood) | 2006 | https://conductscience.org/library/papers/16565432 | PubMed |
| 9 | 17827138 | In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains. | J Antimicrob Chemother | 2007 | https://conductscience.org/library/papers/17827138 | PubMed |
| 10 | 14613958 | Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. | J Antimicrob Chemother | 2003 | https://conductscience.org/library/papers/14613958 | PubMed |
| 11 | 17186236 | Mutagenesis of a bacteriophage lytic enzyme PlyGBS significantly increases its antibacterial activity against group B streptococci. | Appl Microbiol Biotechnol | 2007 | https://conductscience.org/library/papers/17186236 | PubMed |
| 12 | 30642930 | ClyJ Is a Novel Pneumococcal Chimeric Lysin with a Cysteine- and Histidine-Dependent Amidohydrolase/Peptidase Catalytic Domain. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/30642930 | PubMed |
| 13 | 27516758 | PL3 Amidase, a Tailor-made Lysin Constructed by Domain Shuffling with Potent Killing Activity against Pneumococci and Related Species. | Front Microbiol | 2016 | https://conductscience.org/library/papers/27516758 | PubMed |
| 14 | 32291298 | Targeting Hidden Pathogens: Cell-Penetrating Enzybiotics Eradicate Intracellular Drug-Resistant Staphylococcus aureus. | mBio | 2020 | https://conductscience.org/library/papers/32291298 | PubMed |
| 15 | 15231813 | Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium. | J Bacteriol | 2004 | https://conductscience.org/library/papers/15231813 | PubMed |
| 16 | 30889831 | Phage Endolysins as Potential Antimicrobials against Multidrug Resistant Vibrio alginolyticus and Vibrio parahaemolyticus: Current Status of Research and Challenges Ahead. | Microorganisms | 2019 | https://conductscience.org/library/papers/30889831 | PubMed |
| 17 | 27341401 | Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period. | Clin Exp Pharmacol Physiol | 2016 | https://conductscience.org/library/papers/27341401 | PubMed |
| 18 | 28860505 | Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant Enterococcus faecalis infections. | Sci Rep | 2017 | https://conductscience.org/library/papers/28860505 | PubMed |
| 19 | 29776929 | Antibacterial Effects of Phage Lysin LysGH15 on Planktonic Cells and Biofilms of Diverse Staphylococci. | Appl Environ Microbiol | 2018 | https://conductscience.org/library/papers/29776929 | PubMed |
| 20 | 15616283 | Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/15616283 | PubMed |
Cited by78
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 93 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42923362 | Global trends in phage-derived depolymerase research for anti-infective applications: a bibliometric analysis. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42923362 | PubMed |
| 42746328 | Autoimmune disease-associated pathobionts: mechanisms and therapeutic potential of phage-based approaches. | Front Immunol | 2026 | https://conductscience.org/library/papers/42746328 | PubMed |
| 42726361 | A dual-functional dendrimer-based system integrating recombinant endolysin and cinnamic acid for enhanced endolysin stability and antibacterial activity against Acinetobacter baumannii. | World J Microbiol Biotechnol | 2026 | https://conductscience.org/library/papers/42726361 | PubMed |
| 42564788 | Domain shuffling of endolysin LysKB317 to control Limosilactobacillus fermentum in corn mash fermentation. | Biotechnol Rep (Amst) | 2026 | https://conductscience.org/library/papers/42564788 | PubMed |
| 42539602 | Bacteriophage lysins: a promising strategy for combating foodborne pathogens in food safety. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42539602 | PubMed |
| 42505660 | Phage-Derived Endolysins Targeting Cutibacterium acnes: A Scoping Review. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42505660 | PubMed |
| 42467470 | Data mining reveals the diversity of prophage endolysins targeting pathogenic enterococci. | J Gen Virol | 2026 | https://conductscience.org/library/papers/42467470 | PubMed |
| 42347211 | Prophages in Skin Pathogens: From Virulence to Therapy. | Pathogens | 2026 | https://conductscience.org/library/papers/42347211 | PubMed |
| 42283824 | Bacteriophage therapy for multidrug-resistant bacterial infections: recent advances, clinical evidence, and translational challenges. | Arch Microbiol | 2026 | https://conductscience.org/library/papers/42283824 | PubMed |
| 42259805 | Novel endopeptidase overcoming lysostaphin resistance. | Sci Rep | 2026 | https://conductscience.org/library/papers/42259805 | PubMed |
| 42249936 | First experimentally characterised Proteus phage endolysins have distinct metal cofactor dependencies. | Appl Microbiol Biotechnol | 2026 | https://conductscience.org/library/papers/42249936 | PubMed |
| 42207801 | Genomic and functional characterization of a novel halophilic bacteriophage targeting carbapenem-resistant Klebsiella pneumoniae. | PLoS One | 2026 | https://conductscience.org/library/papers/42207801 | PubMed |
| 42176155 | In silico analysis, expression, and characterization of LysStp1 endolysin with L-alanyl-D-glutamate carboxypeptidase activity. | Virus Genes | 2026 | https://conductscience.org/library/papers/42176155 | PubMed |
| 42119891 | Characterization and antibacterial efficacy of the broad-host-range phage P108 against biofilm-forming and methicillin-resistant Staphylococcus aureus. | Virus Res | 2026 | https://conductscience.org/library/papers/42119891 | PubMed |
| 42051596 | Translational barriers to phage endolysin deployment for antimicrobial resistance control in Africa. | Front Antibiot | 2026 | https://conductscience.org/library/papers/42051596 | PubMed |
| 42010135 | Search for effective bacteriolytic enzymes and their combinations for the treatment of polymicrobial biofilm-associated infections. | World J Microbiol Biotechnol | 2026 | https://conductscience.org/library/papers/42010135 | PubMed |
| 41675162 | Skin microbiome engineering: Challenges and opportunities in skin diseases treatment. | IMetaOmics | 2025 | https://conductscience.org/library/papers/41675162 | PubMed |
| 41648009 | Multidrug-resistant Pseudomonas aeruginosa infections: current status, challenges, and prospects of phage therapy. | Front Microbiol | 2025 | https://conductscience.org/library/papers/41648009 | PubMed |
| 41627471 | Phage as control strategy against the foodborne pathogen, Bacillus cereus. | Arch Microbiol | 2026 | https://conductscience.org/library/papers/41627471 | PubMed |
| 41600675 | Avian Pathogenic Escherichia coli: Advances in Pathogenesis, Diagnosis, and Control. | Vet Sci | 2025 | https://conductscience.org/library/papers/41600675 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37101261
GET https://conductscience.org/api/papers/v1/37101261/references?page=2